GLP-1 Weight Loss Guide 2026: How the Medications Work and What to Know
GLP-1 medications have become a major part of medical weight management. But they are not one single drug, and they are not right for everyone. Semaglutide, tirzepatide and the investigational retatrutide each work differently, carry different research behind them, and come with different questions worth asking before you start.
Educational content only. Treatment decisions must be made with a licensed healthcare professional.
Semaglutide Explained
Tirzepatide Explained
Retatrutide Research Status
Side Effects and Safety
Clinician-Led Treatment Options
GLP-1 Beginner’s Guide
Semaglutide Explained
Tirzepatide Explained
Retatrutide Research Status
Side Effects and Safety
Clinician-Led Treatment Options
What Is a GLP-1 Medication?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases naturally after you eat. GLP-1 medications mimic that hormone. They don’t just burn fat. They work on three connected systems: appetite, digestion and blood sugar. In the brain, they reduce hunger signals. In the stomach, they slow how quickly food moves through, which extends the feeling of fullness. In the pancreas, they help regulate insulin release in response to food. Some newer medications add a second or third hormone target, which changes how strong the effect is and what side effects to expect. None of this replaces food choices or activity. It’s a medical tool, used alongside a plan, under supervision.
How GLP-1 Medications Work
Appetite regulation
GLP-1 receptors in the brain reduce hunger signals, which is why appetite often drops noticeably during treatment.
Slower stomach emptying
Food stays in the stomach longer, which extends fullness after meals and can reduce portion sizes naturally.
Blood sugar response
These medications support more stable insulin release after eating, which is part of why some were developed for type 2 diabetes first.
Clinician-guided dosing and monitoring
Dosing typically starts low and increases gradually. A clinician tracks response and side effects along the way.
Semaglutide vs Tirzepatide vs Retatrutide
These three medications are often mentioned together, but they are not interchangeable. The table below breaks down what each one targets and where it currently stands. For a deeper breakdown, read our semaglutide vs tirzepatide vs retatrutide comparison.
| Medication | Hormone targets | Current status | Typical use | Important note |
|---|---|---|---|---|
| Semaglutide | GLP-1 | FDA-approved branded formulations exist for chronic weight management and for type 2 diabetes under different product labels | Usually a once-weekly injection; approved uses and dosing depend on the product | Not every semaglutide product is approved for weight management |
| Tirzepatide | GLP-1 and GIP | FDA-approved branded formulations exist for chronic weight management and for type 2 diabetes under different product labels | Usually a once-weekly injection; approved uses and dosing depend on the product | Targets both GLP-1 and GIP; individual response and side effects vary |
| Retatrutide | GLP-1, GIP and glucagon | Investigational and not approved by any regulatory agency | Available legally only through Lilly clinical trials | Triple hormone target under study. Hume Care does not offer retatrutide |
Where Does Retatrutide Fit In?
Retatrutide gets attention because of its mechanism. It targets three hormone receptors at once: GLP-1, GIP and glucagon. Early trial data generated interest in the results. That is the honest reason it comes up so often in conversations about weight-loss medication.
But clinical-trial results do not make a drug generally available. Lilly states that retatrutide has not been approved by any regulatory agency and is legally available only to participants in its clinical trials. Trial findings measured under controlled conditions do not turn an investigational drug into a routine prescription.
If you come across a website claiming to sell retatrutide as a normal prescription today, treat that as a red flag. A medication still in trials should not be sold as a routine treatment. Be cautious of any source making that claim.
Hume Care does not offer retatrutide. It is not part of their current treatment options, and nothing on this page should be read as suggesting otherwise.
Benefits and Limitations
Possible benefits of suitable clinician-led treatment
- Appetite support
- Structured weight-management support
- Metabolic health support
- Professional monitoring throughout treatment
Limitations to weigh
- Side effects, which vary by person
- Cost, which is often ongoing
- Eligibility restrictions based on health history
- Ongoing clinical supervision requirements
- Medication availability, which can vary
- Results vary from person to person
- Treatment may not suit everyone
Side Effects
Commonly reported side effects with GLP-1 medicines include nausea, vomiting, diarrhoea, constipation, reduced appetite and abdominal discomfort. Gastrointestinal side effects may occur during treatment, including during dose escalation. Their timing, severity and duration vary, so persistent or severe symptoms should be discussed with a clinician.
Serious reactions are possible. This is why ongoing clinician monitoring matters and why changing a dose or combining medicines without medical guidance is unsafe. This page cannot tell you your correct dose or diagnose a symptom.
Who May Be Considered?
There is no single fixed rule for who qualifies for GLP-1 treatment. Eligibility is decided case by case. Read our full GLP-1 eligibility guide for a more detailed explanation. Factors considered may include:
- Medical history
- Current medications
- Weight-related health factors
- Pregnancy or breastfeeding status
- Previous treatment history
- Location, since availability can vary by state
- An independent clinician assessment
Retatrutide Is Not Available Yet. What Can You Explore Now?
Retatrutide remains investigational and is not offered through Hume Care. Eligible US adults interested in currently available GLP-1 weight-management options may complete Hume Care’s online assessment. You can also read our independent Hume Care review before leaving HealthyPA.
If the initial requirements are met, users may be connected with an independent licensed clinician. That clinician independently decides whether treatment is appropriate and which option, if any, may be considered. Completing the assessment does not guarantee treatment, a prescription or access to a particular medication.
Online eligibility assessment
A short questionnaire covering your health background and goals.
Independent clinician review
A licensed clinician reviews your information and determines next steps.
Personalised treatment consideration
Any option considered is based on your individual clinical suitability.
Ongoing programme support
Support continues through the programme if treatment moves forward.
Progress tracking
Tools to help you and your clinician follow how things are going.
Participating US states
Availability varies by state. The assessment will confirm what’s accessible where you live.
Affiliate link. HealthyPA may earn a commission if you proceed. Hume Care does not offer retatrutide. US adults only. Availability varies by state. Completing an assessment does not guarantee treatment or a prescription.
How the Process Works
- Complete the online assessment
- Provide relevant health information
- Receive an independent clinician review
- Discuss options if clinically appropriate
Questions Worth Asking Before You Start
Before committing to any GLP-1 programme, get straight answers to these:
- Who provides the clinical care?
- What medication is being considered?
- Is it branded or compounded?
- What is included in the price?
- Does the programme renew automatically?
- How can it be cancelled?
- What side effects require medical help?
- Is ongoing monitoring included?
Frequently Asked Questions
What does GLP-1 actually mean?
GLP-1 stands for glucagon-like peptide-1, a natural gut hormone. GLP-1 medications are designed to mimic that hormone’s effects on appetite, digestion and blood sugar.
Is a GLP-1 medication the same thing as insulin?
No. Insulin directly lowers blood sugar. GLP-1 medications work differently. They influence how much insulin your body releases in response to food, along with appetite and digestion, but they are a separate class of medication.
What’s the real difference between semaglutide and tirzepatide?
Semaglutide targets one hormone receptor, GLP-1. Tirzepatide targets two, GLP-1 and GIP. That dual action is the main mechanical difference, and it’s part of why the two medications can produce different results for different people.
Is retatrutide available for prescription right now?
No. Lilly states that retatrutide has not been approved by any regulatory agency and is legally available only to participants in its clinical trials.
Does Hume Care offer retatrutide?
No. Hume Care does not provide retatrutide. Its platform may connect eligible US adults with an independent licensed clinician, who decides whether an available GLP-1 option is clinically appropriate.
Who can use a GLP-1 medication?
That depends on individual health history, current medications, weight-related health factors and other clinical details. An independent licensed clinician makes that determination on a case-by-case basis.
What are the most common side effects?
Nausea, vomiting, diarrhoea, constipation, reduced appetite and abdominal discomfort are the most frequently reported. Serious reactions are possible, which is why clinician monitoring matters.
What is a compounded medication?
A compounded medication is prepared by a pharmacy rather than manufactured by the original drug maker. Compounded medications are not FDA-approved in the way branded versions are, and the specifics vary by pharmacy and by state.
Does completing an assessment guarantee a prescription?
No. Completing an assessment does not guarantee treatment or a prescription. An independent licensed clinician reviews your information and decides what, if anything, is appropriate.
Is this available across the entire United States?
Hume Care’s programme is intended for eligible US adults, but availability varies by state. The assessment will show what applies to your location.
How long does GLP-1 treatment typically last?
Duration depends on the individual treatment plan and clinical response, and it’s decided between you and your clinician. There’s no fixed timeline that applies to everyone.
What happens after treatment stops?
Responses vary by person. Some of the appetite and digestion effects tend to fade once the medication is discontinued, which is why many programmes emphasize an ongoing plan rather than a short course. Talk to your clinician about what to expect for your specific situation.
The Bottom Line
FDA-approved branded semaglutide and tirzepatide options are available for specific uses, while retatrutide remains investigational and is not offered through Hume Care. Eligible US adults who want to explore currently available options can complete Hume Care’s online assessment. Hume Care does not decide treatment: an independent licensed clinician reviews the case and determines whether any treatment or medication is clinically appropriate.
Explore Clinician-Led GLP-1 Options
Affiliate link. HealthyPA may earn a commission if you proceed. Hume Care does not offer retatrutide. US adults only. Availability varies by state. Completing an assessment does not guarantee treatment or a prescription.
References
- FDA prescribing information for Wegovy (semaglutide)
- FDA approval announcement for Zepbound (tirzepatide) for chronic weight management
- FDA concerns about unapproved GLP-1 drugs used for weight loss
- ClinicalTrials.gov: Phase 3 retatrutide study in adults with obesity or overweight
- Eli Lilly: What to know about retatrutide
- NEJM: Once-weekly semaglutide in adults with overweight or obesity
- NEJM: Tirzepatide once weekly for the treatment of obesity
- NEJM: Triple-hormone-receptor agonist retatrutide for obesity
- Hume Care official website
- Hume Care Terms of Service